glp‑1 analog titration
63% Weight Loss With Semaglutide In MC4R Trial
Semaglutide provides the quickest and most lasting weight loss for MC4R-deficient obesity, cutting BMI by 63% in a 26-week trial. The double-blind, placebo-controlled study enrolled adults with confirmed MC4R mutations, showing that the drug’s appetite-suppressing action outperformed previous benchmarks. Medical Disclaimer: This article is for informational purposes only and